摘要
目的探讨晚期非小细胞肺癌化疗疗效与血清C反应蛋白(CRP)、血清白蛋白(Alb)检测的临床意义。方法 150例Ⅳ期非小细胞肺癌患者接受一线含铂两药方案化疗,评价化疗疗效并测定治疗前后CRP及Alb水平的变化,同时对可能影响预后的因素进行分析。结果 (1)150例患者均可评价疗效及不良反应。总有效率(RR)为29.3%,疾病控制率(DCR)为73.3%,中位无进展生存期(TTP)6.0月(1-54月);150例患者1年总生存率为66.7%,2年总生存率为30.0%。(2)CRP在不同的病理类型中比较,肺鳞癌及未分化癌组明显高于腺癌组,差异有统计学意义(P<0.05)。(3)治疗前、后血清CRP变化与疗效有关;治疗前、后血清CRP和Alb联合检测结果与生存情况相关。结论晚期非小细胞肺癌一线化疗方案为含铂两药方案;血清CRP、Alb的测定对晚期非小细胞肺癌患者化疗后的病情评估、预后判断有重要临床意义。
Objective To evaluate the results of chemotherapy and the clinical significance of serum C-reactive protein （CRP） and serum albumin （Alb） in patients of advanced non-small cell lung cancer（NSCLC）. Methods 150 patients with nnreseeted IV stage NSCLC received two drug regimens containing tplatinum as first-line chemotherapy. The results of chemotherapy,serum CRP amt Alb levels were detected in advanced NSCLC patients during a week before the treatment and eight weeks after the treatment,and the prognostic predicators were analyzed. Results （ 1 ） Toxicity and clinical efficacy were evaluated in all the 150 patients, The overall response rate was 29.3% and disease control rate was 73.3%. The meidan time to progress （TTP） was 6.0 months, The 1-year survival rate was 66.7% ,2-year live rate was 30.0%. （2）The mean of baseline CRP levels in adenocarcinoma was （9.82 ± 15.53 ） mg/L. The basline CRP level in squamous carcinoma and poorly differentiated lung cancers was significantly higher than that in adenocarcinoma. （3）The changed levels in CRP and Alb before and after chemotherapy were closely correlated with the survival. Conclusions The first-line chemotherapy is two drug regimens containing platinum in NSCLC. Combined detection of two serum markers（ CRP and Alb） contributes to pathogenetic condition judgement and therapeutic effect monitoring of NSCLC.
出处
《实用肿瘤杂志》
CAS
2013年第5期509-512,共4页
Journal of Practical Oncology
基金
上海市闵行区卫生局科研课题资助项目(2010MW14)
关键词
癌
非小细胞肺/药物疗法
C反应蛋白
血清白蛋白
预后
carcinoma, non-small cell lung/drug therapy
C-reactive protein
serum albumin
prognosis
